drugset / Trial / NCT06888193

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193

Phase 1 Recruiting 20 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelOther

Summary

Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.

Timeline

Start
2025-11-05
Primary completion
2027-05-03
Completion
2027-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimekizumab Monoclonal antibody